(Q34775684)

4 August 2017

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection (English)

1 reference

4 August 2017

1 reference

1 reference

1 reference

1 reference

1 reference

8

Asa Alsiö

0 references

Martin Lagging

Martin Lagging

1

0 references

Kristoffer Hellstrand

Kristoffer Hellstrand

9

0 references

Martti Färkkilä

Martti Färkkilä

4

0 references

Amar P. Dhillon

7

Amar P Dhillon

1 reference

4 August 2017

10

Johan Westin

1 reference

4 August 2017

2

Nina Langeland

1 reference

4 August 2017

5

Mads Rauning Buhl

1 reference

4 August 2017

6

Kristine Mørch

1 reference

4 August 2017

11

Gunnar Norkrans

1 reference

4 August 2017

NORDynamIC Study Group

12

NORDynamIC Study Group

1 reference

4 August 2017

Court Pedersen

3

1 reference

4 August 2017

Asa Alsiö

8

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

4 August 2017

1 reference

4 August 2017

47

1 reference

4 August 2017

6

1 reference

4 August 2017

1837-1845

1 reference

Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis

4 August 2017

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

7 January 2021

Hepatitis C virus infection is associated with the development of hepatocellular carcinoma

1 reference

7 January 2021

Progression of fibrosis in untreated patients with hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

7 January 2021

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

7 January 2021

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

1 reference

7 January 2021

Genotyping of hepatitis C virus by Taqman real-time PCR.

1 reference

7 January 2021

Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection

1 reference

7 January 2021

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

1 reference

7 January 2021

Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial

1 reference

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

7 January 2021

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.22253

1 reference

4 August 2017

1 reference